Earnings summaries and quarterly performance for LB PHARMACEUTICALS.
Research analysts covering LB PHARMACEUTICALS.
Recent press releases and 8-K filings for LBRX.
LB Pharmaceuticals Announces $100 Million Private Placement
LBRX
New Projects/Investments
- LB Pharmaceuticals announced a $100.0 million private placement of common stock and pre-funded warrants to institutional investors.
- The purchase price for each share of common stock is $21.17, and for each pre-funded warrant is $21.1699.
- The company expects the private placement to close on or about February 6, 2026.
- Net proceeds will fund a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder and for general corporate purposes.
- The Phase 2 trial for LB-102 is expected to initiate in early 2027, with topline results anticipated in the first half of 2029.
2 days ago
LB Pharmaceuticals Updates on Clinical Programs and Financial Runway
LBRX
New Projects/Investments
Guidance Update
- LB Pharmaceuticals plans to initiate its Phase 3 study for schizophrenia in Q1 2026, with top-line data anticipated in the first half of 2027. The study was upsized from 400 to 460 patients to increase statistical power from 80% to 85%.
- The company secured approximately $300 million net from its recent IPO, providing a cash runway into the second quarter of 2028, which is sufficient to fund the schizophrenia trial, the bipolar depression trial, and all NDA-enabling studies.
- LB Pharmaceuticals intends to start a Phase 2 clinical trial for bipolar depression in Q1 2026, targeting 320 patients across 30 sites in the U.S..
- The FDA has concurred that the Phase 2 trial for LB-102 had registrational quality, potentially allowing for a streamlined path to approval with just one successful Phase 3 trial.
Dec 3, 2025, 2:30 PM
LB Pharmaceuticals Provides Updates on Clinical Trials and Financial Position
LBRX
New Projects/Investments
Guidance Update
- LB Pharmaceuticals (LBRX) plans to initiate its Phase 3 study for schizophrenia in Q1 2026, with top-line data expected in the first half of 2027. The study was upsized from 400 to 460 patients to increase statistical power from 80% to 85%.
- The company also plans to commence a Phase 2 clinical trial for bipolar depression in Q1 2026, targeting 320 patients across 30 U.S. sites.
- Following its IPO, LB Pharmaceuticals raised approximately $300 million net and has a cash runway into Q2 2028, funding both the schizophrenia and bipolar depression trials.
- LB-102, a derivative of Amisulpride, is positioned for competitive efficacy and a potential best-in-class safety profile with a low rate of extrapyramidal symptoms (EPS) (1% at 50mg dose in Phase 2). It also shows potential for differentiation in cognition and negative symptoms.
Dec 3, 2025, 2:30 PM
LB Pharmaceuticals Updates on Clinical Trials and Financial Runway
LBRX
New Projects/Investments
Guidance Update
- LB Pharmaceuticals plans to initiate its Phase III study for schizophrenia in Q1 2026, upsizing the trial from 400 to 460 patients to increase statistical power from 80% to 85%, with top-line data anticipated in the first half of 2027.
- A Phase II clinical trial for bipolar depression is also scheduled to begin in Q1 2026, targeting approximately 320 patients across 30 U.S. sites.
- The company raised approximately $300 million net from its recent IPO, providing a cash runway into the second quarter of 2028, which is expected to fund both the schizophrenia and bipolar depression trials.
- The FDA has indicated that a single successful Phase III trial for LB-102 could be sufficient for approval, and the drug demonstrated a low rate of extrapyramidal symptoms (EPS) of 1% at the 50 mg dose in its Phase II trial.
Dec 3, 2025, 2:30 PM
LB Pharmaceuticals (LBRX) Provides Update on Clinical Programs and Financial Outlook
LBRX
New Projects/Investments
Guidance Update
- LB Pharmaceuticals (LBRX) recently completed an IPO, raising $300 million, which funds the Phase 3 schizophrenia trial, NDA enabling studies, and the Phase 2 bipolar depression trial, extending the cash runway into Q2 2028.
- The company is developing LB102, a novel antipsychotic for schizophrenia and mood disorders, which demonstrated highly statistically significant efficacy and a potential class-leading safety profile in Phase 2 schizophrenia data.
- Key upcoming clinical milestones include top-line data for the Phase 3 schizophrenia trial (targeting 460 patients) in H2 2027, and data from the registrational quality Phase 2 bipolar depression trial (enrolling 320 patients) in Q1 2028.
- LB102 has composition of matter intellectual property extending to 2041, with the potential to generate billions of revenue.
Nov 13, 2025, 2:20 PM
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
LBRX
Management Change
Hiring
New Projects/Investments
- LB Pharmaceuticals Inc. announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025.
- Ms. Pai Panandiker brings over 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and successful product launches.
- Her expertise is expected to be instrumental in advancing LB-102, a Phase 3-ready therapy for schizophrenia and bipolar depression, toward registration and commercialization.
Nov 12, 2025, 1:17 PM
LB Pharmaceuticals Reports Q3 2025 Financial Results and Clinical Progress
LBRX
Earnings
New Projects/Investments
Board Change
- LB Pharmaceuticals Inc. reported a net loss of $3.6 million for Q3 2025, a significant reduction from a net loss of $14.2 million in Q3 2024. Research and development expenses decreased to $2.4 million in Q3 2025 from $10.7 million in Q3 2024, primarily due to lower clinical trial expenses.
- Following an upsized initial public offering (IPO) in September 2025 that generated $327.8 million in gross proceeds, the company's cash, cash equivalents, and marketable securities stood at approximately $314.5 million as of September 30, 2025. This cash position is anticipated to support operations into the second quarter of 2028.
- The company announced positive results from its Phase 2 NOVA 1 clinical trial of LB-102 in acute schizophrenia, showing robust and significant treatment effects on cognitive deficits. LB Pharmaceuticals plans to initiate a Phase 3 trial for acute schizophrenia and a Phase 2 trial for bipolar depression in Q1 2026, with topline data expected in H2 2027 and Q1 2028, respectively.
- In September and October 2025, the company appointed William Kane and Rekha Hemrajani to its Board of Directors and James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs.
Nov 6, 2025, 1:13 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more